LFST · Insider Trading
LifeStance Health Group, Inc. Common Stock
Every open-market purchase and sale reported by LFST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-24 | David Bourdon | Chief Executive Officer | G | — | — |
| 2026-09-15 | TPG GP A, LLC | 10%+ Owner | Sell | −55,229,115 | −$678.77M |
| 2026-09-04 | David Bourdon | Chief Executive Officer | J | −150,000 | — |
| 2026-09-04 | Vukasin Paunovich | Chief Technology Officer | Sell | −42,067 | −$541.40K |
| 2026-08-26 | Ann Varanakis | Chief People Officer | F | −8,156 | −$99.18K |
| 2026-08-18 | Teresa DeLuca | Director | Sell | −7,500 | −$95.10K |
| 2026-08-14 | Teresa DeLuca | Director | Sell | −20,441 | −$249.99K |
| 2026-08-13 | Kenneth A Burdick | Director | Sell | −500,000 | −$5.75M |
| 2026-08-12 | Lisa K Miller | Chief Operating Officer | Sell | −47,912 | −$519.85K |
| 2026-08-12 | Vukasin Paunovich | Chief Technology Officer | Sell | −44,394 | −$481.67K |
| 2026-08-12 | James G Coulter | 10%+ Owner | Sell | −40,929,621 | −$434.67M |
| 2026-07-14 | Kenneth A Burdick | Director | A | +45,495 | — |
| 2026-07-07 | Sarah Personette | Director | A | +17,746 | — |
| 2026-07-07 | Teresa DeLuca | Director | A | +17,746 | — |
| 2026-07-07 | Thurman Justice | Director | A | +35,492 | — |
| 2026-07-07 | Lori Goltermann | Director | A | +35,492 | — |
| 2026-07-07 | Eric P Palmer | Director | A | +17,746 | — |
| 2026-07-07 | Robert Bessler | Director | A | +17,746 | — |
| 2026-06-15 | Vukasin Paunovich | Chief Technology Officer | F | −17,456 | −$150.30K |
| 2026-05-14 | Darren M. Black | Director | Sell | −5,899,661 | −$47.32M |
| 2026-05-14 | Eric Shuey | Director | Sell | −243,362 | −$1.95M |
| 2026-05-14 | Robert Bessler | Director | Sell | −575,034 | −$4.61M |
| 2026-05-14 | James G Coulter | 10%+ Owner | Sell | −84,845,829 | −$680.46M |
| 2026-05-11 | Robert Bessler | Director | Sell | −75,000 | −$641.25K |
| 2026-04-27 | Robert Bessler | Director | Sell | −69,899 | −$492.40K |
| 2026-04-23 | Robert Bessler | Director | Sell | −5,101 | −$35.76K |
| 2026-04-03 | Ryan Pardo | See Remarks | F | −9,376 | −$59.73K |
| 2026-03-26 | Ryan McGroarty | See Remarks | F | −24,255 | −$156.44K |
| 2026-03-19 | Ryan McGroarty | See Remarks | F | −47,594 | −$327.92K |
| 2026-03-11 | Lisa K Miller | Chief Operating Officer | MIXED | −1,376 | −$194.94K |
| 2026-03-11 | Kenneth A Burdick | Director | MIXED | +413,295 | −$2.26M |
| 2026-03-11 | David Bourdon | Chief Executive Officer | MIXED | +180,162 | −$1.03M |
| 2026-03-11 | Vukasin Paunovich | Chief Technology Officer | MIXED | +44,394 | −$128.12K |
| 2026-03-11 | Ryan McGroarty | See Remarks | MIXED | +116,473 | −$529.12K |
| 2026-03-11 | Ryan Pardo | See Remarks | MIXED | +79,365 | −$460.21K |
| 2026-03-11 | Ann Varanakis | Chief People Officer | MIXED | +41,662 | −$310.69K |
| 2026-03-09 | Stephanie Carin Eken | Chief Medical Officer | A | +115,107 | — |
| 2026-03-09 | Ann Varanakis | Chief People Officer | MIXED | +64,765 | −$149.45K |
| 2026-03-09 | David Bourdon | Chief Executive Officer | MIXED | +329,846 | −$456.25K |
| 2026-03-09 | Ryan McGroarty | See Remarks | A | +179,856 | — |
| 2026-03-09 | Ryan Pardo | See Remarks | MIXED | +107,642 | −$151.45K |
| 2026-03-09 | Lisa K Miller | See Remarks | MIXED | +86,324 | −$149.62K |
| 2026-03-09 | Kenneth A Burdick | Director | F | −424,551 | −$3.02M |
| 2026-03-09 | Vukasin Paunovich | Chief Technology Officer | A | +86,331 | — |
| 2026-03-04 | Darren M. Black | Director | Sell | −4,314,939 | −$30.25M |
| 2026-03-04 | Jon Winkelried | 10%+ Owner | Sell | −62,055,183 | −$435.01M |
| 2025-12-23 | Robert Bessler | Director | Sell | −121,643 | −$856.37K |
| 2025-12-19 | Ann Varanakis | Chief People Officer | Sell | −50,000 | −$345.00K |
| 2025-12-19 | Robert Bessler | Director | Sell | −6,442 | −$45.09K |
| 2025-12-16 | Robert Bessler | Director | Sell | −92,001 | −$644.80K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jon Winkelried | 10%+ Owner | 140,026,557 | $1.83B |
| James G Coulter | 10%+ Owner | 98,101,407 | $1.28B |
| TPG GP A, LLC | 10%+ Owner | 79,691,702 | $1.04B |
| SUMMIT INVESTORS GE IX/VC IV, LLC | — | 33,524,715 | $437.83M |
| Darren M. Black | Director | 23,310,115 | $304.43M |
| Silversmith Partners I GP, LLC | 10%+ Owner | 14,324,197 | $187.07M |
| Ryan Pardo | See Remarks | 3,644,886 | $47.60M |
| Kenneth A Burdick | Director | 3,017,321 | $39.41M |
| Pablo Pantaleoni | Chief Digital Officer | 1,437,881 | $18.78M |
| David Bourdon | Chief Executive Officer | 1,248,247 | $16.30M |
| Eric Shuey | Director | 961,544 | $12.56M |
| Ryan McGroarty | See Remarks | 772,235 | $10.09M |
| Ann Varanakis | Chief People Officer | 413,881 | $5.41M |
| Lisa K Miller | Chief Operating Officer | 281,289 | $3.67M |
| Vukasin Paunovich | Chief Technology Officer | 205,379 | $2.68M |
| Teresa DeLuca | Director | 133,456 | $1.74M |
| Stephanie Carin Eken | Chief Medical Officer | 115,107 | $1.50M |
| Robert Bessler | Director | 111,728 | $1.46M |
| Ujjwal Ramtekkar | Chief Medical Officer | 103,916 | $1.36M |
| Sarah Personette | Director | 92,512 | $1.21M |
| Eric P Palmer | Director | 89,174 | $1.16M |
| Lori Goltermann | Director | 35,492 | $463.53K |
| Thurman Justice | Director | 35,492 | $463.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LFST quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.